文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Efficacy of lenalidomide for relapsed or refractory T lymphoblastic lymphoma/leukemia after allogeneic hematopoietic stem cell transplantation.

作者信息

Liang Dan, Wei Cong, Zhang Xiaoting, Yang Jilong, Zheng Yaling, Du Jingwen, Wang Liang, Deng Lan

机构信息

Department of Hematology, Zhujiang Hospital, Southern Medical University, Guangzhou, China.

Department of Hematology, Beijing TongRen Hospital, Capital Medical University, Beijing, China.

出版信息

Leuk Lymphoma. 2021 Oct;62(10):2521-2525. doi: 10.1080/10428194.2021.1919665. Epub 2021 May 17.

DOI:10.1080/10428194.2021.1919665
PMID:33993826
Abstract
摘要

相似文献

[1]
Efficacy of lenalidomide for relapsed or refractory T lymphoblastic lymphoma/leukemia after allogeneic hematopoietic stem cell transplantation.

Leuk Lymphoma. 2021-10

[2]
Treatment with mogamulizumab or lenalidomide for relapsed adult T-cell leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation: The Nagasaki transplant group experience.

Hematol Oncol. 2020-1-26

[3]
CAR-T cells and allogeneic hematopoietic stem cell transplantation for relapsed/refractory B-cell acute lymphoblastic leukemia.

Immunotherapy. 2017-10

[4]
Allogeneic Donor-Derived Anti-CD19 CAR T Cell Is a Promising Therapy for Relapsed/Refractory B-ALL After Allogeneic Hematopoietic Stem-Cell Transplantation.

Clin Lymphoma Myeloma Leuk. 2020-9

[5]
The effect of graft-versus-host disease on outcomes after allogeneic stem cell transplantation for refractory lymphoblastic lymphoma in children and young adults.

Pediatr Blood Cancer. 2019-12-26

[6]
Fludarabine, amsacrine, high-dose cytarabine and 12 Gy total body irradiation followed by allogeneic hematopoietic stem cell transplantation is effective in patients with relapsed or high-risk acute lymphoblastic leukemia.

Bone Marrow Transplant. 2009-5-11

[7]
Long-term follow-up of CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation.

Cytotherapy. 2020-12

[8]
Development of BCR-ABL positive acute lymphoblastic leukemia in donor cells after allogeneic hematopoietic cell transplantation for Philadelphia-positive acute lymphoblastic leukemia.

Bone Marrow Transplant. 2004-7

[9]
Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy followed by haploidentical HSCT for relapsed/refractory acute lymphoblastic leukemia: a multi-center retrospective study.

J Hematol Oncol. 2020-5-4

[10]
Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.

Cytotherapy. 2001

引用本文的文献

[1]
Role of allogeneic hematopoietic stem cell transplantation in patients with high-risk T-cell lymphoblastic leukaemia/lymphoma: an analysis of clinical outcomes.

Bone Marrow Transplant. 2024-3

[2]
PET/CT Evaluation of the Effect of Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of T-Cell Lymphoblastic Lymphoma.

Contrast Media Mol Imaging. 2022

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索